Young Ho Lee1, Sang-Cheol Bae2. 1. Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine, 73, Inchon-ro, 02841, Seoul, Seongbuk-gu, Korea (Republic of). lyhcgh@korea.ac.kr. 2. Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea (Republic of).
Abstract
OBJECTIVE: To systematically review evidence regarding the relationship between circulating vascular endothelial growth factor (VEGF) levels and rheumatoid arthritis (RA), the correlation between serum VEGF levels and RA activity, and the association between VEGF polymorphisms and RA susceptibility. METHODS: We conducted a meta-analysis of the serum/plasma VEGF levels in patients with RA and controls, the correlation coefficients between the circulating VEGF levels and disease activity in patients with RA, and the association between VEGF -2578 A/C, -634 C/G, +936 T/C, and -1154 A/G polymorphisms and the risk for RA. RESULTS: In total, 13 studies including 2508 patients with RA and 2489 controls were included. Meta-analysis revealed that VEGF level was significantly higher in the RA than in the control group (standard mean difference [SMD] = 1.480, 95% confidence interval [CI] = 0.71-2.241, p = 1.4 × 10-4). Stratification by adjustment for age and gender revealed significantly higher VEGF levels for the adjustment and non-adjustment groups in the RA group (SMD = 1.360, 95% CI = 0.445-2.276, p = 0.004; SMD = 1.557, 95% CI = 0.252-2.861, p = 0.019, respectively). Meta-analysis of correlation coefficients showed a significantly positive correlation between circulating VEGF levels and disease activity in RA, and between circulating VEGF and C‑reactive protein levels. However, no association was found between RA and the VEGF -2578 A/C, -634 C/G, +936 T/C, and -1154 A/G polymorphisms. CONCLUSION: Our meta-analysis revealed significantly higher circulating VEGF levels in patients with RA and a positive correlation between VEGF levels and disease activity in RA, but no association between the VEGF -2578 A/C, -634 C/G, +936 T/C, and -1154 A/G polymorphisms and the development of RA.
OBJECTIVE: To systematically review evidence regarding the relationship between circulating vascular endothelial growth factor (VEGF) levels and rheumatoid arthritis (RA), the correlation between serum VEGF levels and RA activity, and the association between VEGF polymorphisms and RA susceptibility. METHODS: We conducted a meta-analysis of the serum/plasma VEGF levels in patients with RA and controls, the correlation coefficients between the circulating VEGF levels and disease activity in patients with RA, and the association between VEGF -2578 A/C, -634 C/G, +936 T/C, and -1154 A/G polymorphisms and the risk for RA. RESULTS: In total, 13 studies including 2508 patients with RA and 2489 controls were included. Meta-analysis revealed that VEGF level was significantly higher in the RA than in the control group (standard mean difference [SMD] = 1.480, 95% confidence interval [CI] = 0.71-2.241, p = 1.4 × 10-4). Stratification by adjustment for age and gender revealed significantly higher VEGF levels for the adjustment and non-adjustment groups in the RA group (SMD = 1.360, 95% CI = 0.445-2.276, p = 0.004; SMD = 1.557, 95% CI = 0.252-2.861, p = 0.019, respectively). Meta-analysis of correlation coefficients showed a significantly positive correlation between circulating VEGF levels and disease activity in RA, and between circulating VEGF and C‑reactive protein levels. However, no association was found between RA and the VEGF -2578 A/C, -634 C/G, +936 T/C, and -1154 A/G polymorphisms. CONCLUSION: Our meta-analysis revealed significantly higher circulating VEGF levels in patients with RA and a positive correlation between VEGF levels and disease activity in RA, but no association between the VEGF -2578 A/C, -634 C/G, +936 T/C, and -1154 A/G polymorphisms and the development of RA.
Authors: Kathryn K Ridout; Samuel J Ridout; Lawrence H Price; Srijan Sen; Audrey R Tyrka Journal: J Affect Disord Date: 2015-12-02 Impact factor: 4.839
Authors: Majid Shahbazi; Anthony A Fryer; Vera Pravica; Iain J Brogan; Helen M Ramsay; Ian V Hutchinson; Paul N Harden Journal: J Am Soc Nephrol Date: 2002-01 Impact factor: 10.121
Authors: Anna Kuryliszyn-Moskal; Piotr Adrian Klimiuk; Stanisław Sierakowski; Mariusz Ciolkiewicz Journal: Clin Rheumatol Date: 2005-10-25 Impact factor: 2.980
Authors: P A Klimiuk; S Sierakowski; R Latosiewicz; J P Cylwik; B Cylwik; J Skowronski; J Chwiecko Journal: Ann Rheum Dis Date: 2002-09 Impact factor: 19.103
Authors: S W Han; G W Kim; J S Seo; S J Kim; K H Sa; J Y Park; J Lee; S Y Kim; J J Goronzy; C M Weyand; Y M Kang Journal: Rheumatology (Oxford) Date: 2004-06-22 Impact factor: 7.580
Authors: Elizaveta A Shatunova; Maksim A Korolev; Vitaly O Omelchenko; Yuliya D Kurochkina; Anna S Davydova; Alya G Venyaminova; Mariya A Vorobyeva Journal: Biomedicines Date: 2020-11-22